New combo therapy aims to boost esophageal cancer survival
NCT ID NCT07359443
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new approach for people with a type of esophageal cancer. Participants receive standard chemotherapy followed by a special MRI-guided radiation treatment. The main goal is to find the safest radiation dose and see if this combination can better control the tumor before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Medical Center Utrecht
RECRUITINGUtrecht, Utrecht, 3582CX, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••